| Gene symbol | AGT | Synonyms | ANHU, SERPINA8, hFLT1 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q42.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | angiotensinogen | ||||
| GTO ID | GTC2649 |
| Trial ID | NCT04836182 |
| Disease | Heart Failure |
| Altered gene | AGT |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 757456|IONIS-AGT-LRx |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production, Administered Subcutaneously Over 12 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction |
| Year | 2021 |
| Country | Hungary|Poland|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 757456-CS5|2020-005878-10 |
| Vector information | |||
|
|||
| Cohort1: IONIS-AGT-LRx | |||||||||
|
|||||||||
| Cohort2: Placebo | |||||||||
|
|||||||||